000141156 001__ 141156
000141156 005__ 20240229105121.0
000141156 0247_ $$2doi$$a10.1016/j.eururo.2018.07.024
000141156 0247_ $$2pmid$$apmid:30077399
000141156 0247_ $$2ISSN$$a0302-2838
000141156 0247_ $$2ISSN$$a1421-993X
000141156 0247_ $$2ISSN$$a1873-7560
000141156 0247_ $$2altmetric$$aaltmetric:46104510
000141156 037__ $$aDKFZ-2018-01687
000141156 041__ $$aeng
000141156 082__ $$a610
000141156 1001_ $$aWatts, Eleanor L$$b0
000141156 245__ $$aLow Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies.
000141156 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2018
000141156 3367_ $$2DRIVER$$aarticle
000141156 3367_ $$2DataCite$$aOutput Types/Journal article
000141156 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1540554248_23500$$xEditorial
000141156 3367_ $$2BibTeX$$aARTICLE
000141156 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141156 3367_ $$00$$2EndNote$$aJournal Article
000141156 520__ $$aExperimental and clinical evidence implicates testosterone in the aetiology of prostate cancer. Variation across the normal range of circulating free testosterone concentrations may not lead to changes in prostate biology, unless circulating concentrations are low. This may also apply to prostate cancer risk, but this has not been investigated in an epidemiological setting.To examine whether men with low concentrations of circulating free testosterone have a reduced risk of prostate cancer.Analysis of individual participant data from 20 prospective studies including 6933 prostate cancer cases, diagnosed on average 6.8 yr after blood collection, and 12 088 controls in the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group.Odds ratios (ORs) of incident overall prostate cancer and subtypes by stage and grade, using conditional logistic regression, based on study-specific tenths of calculated free testosterone concentration.Men in the lowest tenth of free testosterone concentration had a lower risk of overall prostate cancer (OR=0.77, 95% confidence interval [CI] 0.69-0.86; p<0.001) compared with men with higher concentrations (2nd-10th tenths of the distribution). Heterogeneity was present by tumour grade (phet=0.01), with a lower risk of low-grade disease (OR=0.76, 95% CI 0.67-0.88) and a nonsignificantly higher risk of high-grade disease (OR=1.56, 95% CI 0.95-2.57). There was no evidence of heterogeneity by tumour stage. The observational design is a limitation.Men with low circulating free testosterone may have a lower risk of overall prostate cancer; this may be due to a direct biological effect, or detection bias. Further research is needed to explore the apparent differential association by tumour grade.In this study, we looked at circulating testosterone levels and risk of developing prostate cancer, finding that men with low testosterone had a lower risk of prostate cancer.
000141156 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000141156 588__ $$aDataset connected to CrossRef, PubMed,
000141156 7001_ $$aAppleby, Paul N$$b1
000141156 7001_ $$aPerez-Cornago, Aurora$$b2
000141156 7001_ $$aBueno-de-Mesquita, H Bas$$b3
000141156 7001_ $$aChan, June M$$b4
000141156 7001_ $$aChen, Chu$$b5
000141156 7001_ $$aCohn, Barbara A$$b6
000141156 7001_ $$aCook, Michael B$$b7
000141156 7001_ $$aFlicker, Leon$$b8
000141156 7001_ $$aFreedman, Neal D$$b9
000141156 7001_ $$aGiles, Graham G$$b10
000141156 7001_ $$aGiovannucci, Edward$$b11
000141156 7001_ $$aGislefoss, Randi E$$b12
000141156 7001_ $$aHankey, Graeme J$$b13
000141156 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b14$$udkfz
000141156 7001_ $$aKnekt, Paul$$b15
000141156 7001_ $$aKolonel, Laurence N$$b16
000141156 7001_ $$aKubo, Tatsuhiko$$b17
000141156 7001_ $$aLe Marchand, Loïc$$b18
000141156 7001_ $$aLuben, Robert N$$b19
000141156 7001_ $$aLuostarinen, Tapio$$b20
000141156 7001_ $$aMännistö, Satu$$b21
000141156 7001_ $$aMetter, E Jeffrey$$b22
000141156 7001_ $$aMikami, Kazuya$$b23
000141156 7001_ $$aMilne, Roger L$$b24
000141156 7001_ $$aOzasa, Kotaro$$b25
000141156 7001_ $$aPlatz, Elizabeth A$$b26
000141156 7001_ $$aQuirós, J Ramón$$b27
000141156 7001_ $$aRissanen, Harri$$b28
000141156 7001_ $$aSawada, Norie$$b29
000141156 7001_ $$aStampfer, Meir$$b30
000141156 7001_ $$aStanczyk, Frank Z$$b31
000141156 7001_ $$aStattin, Pär$$b32
000141156 7001_ $$aTamakoshi, Akiko$$b33
000141156 7001_ $$aTangen, Catherine M$$b34
000141156 7001_ $$aThompson, Ian M$$b35
000141156 7001_ $$aTsilidis, Konstantinos K$$b36
000141156 7001_ $$aTsugane, Shoichiro$$b37
000141156 7001_ $$aUrsin, Giske$$b38
000141156 7001_ $$aVatten, Lars$$b39
000141156 7001_ $$aWeiss, Noel S$$b40
000141156 7001_ $$aYeap, Bu B$$b41
000141156 7001_ $$aAllen, Naomi E$$b42
000141156 7001_ $$aKey, Timothy J$$b43
000141156 7001_ $$aTravis, Ruth C$$b44
000141156 773__ $$0PERI:(DE-600)1482253-2$$a10.1016/j.eururo.2018.07.024$$gVol. 74, no. 5, p. 585 - 594$$n5$$p585 - 594$$tEuropean urology$$v74$$x0302-2838$$y2018
000141156 909CO $$ooai:inrepo02.dkfz.de:141156$$pVDB
000141156 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000141156 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000141156 9141_ $$y2018
000141156 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000141156 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000141156 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR UROL : 2017
000141156 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141156 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141156 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141156 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000141156 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000141156 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141156 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000141156 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141156 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141156 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000141156 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000141156 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bEUR UROL : 2017
000141156 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebserkrankungen$$x0
000141156 980__ $$ajournal
000141156 980__ $$aVDB
000141156 980__ $$aI:(DE-He78)C020-20160331
000141156 980__ $$aUNRESTRICTED